Answers are grounded in this paper and cite their sources.
Amyloid-PET appears to have moderate to good diagnostic accuracy in differentiating patients with probable CAA from cognitively normal healthy controls or patients with deep ICH. Given that amyloid-PET labels both cerebrovascular and parenchymal amyloid, a negative scan might be useful to rule out CAA in the appropriate clinical setting.
No takes yet. Share an insight, caveat, or question.
Charidimou et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: